Abstract
Purpose: The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries in patients with non-alcoholic fatty liver disease (NAFLD). Methods: Four patients with biopsy proven NAFLD were enrolled. Oral moexipril 15 mg/day was administered for 1 year to three patients. Results: No significant changes in serum alkaline phosphatase (96 ± 32 vs. 93 ± 6 U/L, P= 0.9), total bilirubin (1.5 ± 0.9 vs. 2.1 ± 0.3 mg/dl, P= 0.7), aspartate aminotransferase (48 ± 9 vs. 44 ± 23 U/L, P= 0.4), albumin (4.4 ± 0.3 vs. 4.2 ± 0.6 g/dl, P= 0.9) were noted after 1 year of treatment. One of the 3 patients who received medication withdrew from the study at 6 months. No major adverse reactions were observed, but 2 out of 3 patients complained of increased fatigue. Conclusion: Moexipril was not clinically beneficial to patients with NAFLD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
